Literature DB >> 32231538

Yttrium-90 Radioembolization of Metastatic Adrenocortical Carcinoma to the Liver following Systemic Chemotherapy and Surgical Resection of the Primary Lesion.

Nicholas Pigg1, Daniel Aboubechara1, Roberto Fourzali1, Brian Baigorri1.   

Abstract

Use of yttrium-90 (Y-90) is used for primary liver tumors and a handful of liver metastatic lesions. Y-90 treatment for metastatic adrenocortical carcinoma (ACC) to the liver is currently off-label, with one previously documented case report. In this case report, we present a 52-year-old woman with ACC and extensive liver metastatic disease. After failed chemotherapy, multidisciplinary discussion suggested potential Y-90 treatment for palliative purposes. After undergoing Y-90 treatment separately to the right and then the left hepatic lobes, subsequent patient visits demonstrated significantly improved clinical function as well as complete radiographic resolution of liver metastatic disease mainly from ACC. This case report demonstrates the potential efficacy of Y-90 for off-label uses in liver metastatic disease. This case and similar cases may open the door to a wide variety of potential indications for Y-90 treatment.
Copyright © 2020 by S. Karger AG, Basel.

Entities:  

Keywords:  Adrenocortical carcinoma; Hepatic metastases; Yttrium-90 radioembolization

Year:  2020        PMID: 32231538      PMCID: PMC7098384          DOI: 10.1159/000504779

Source DB:  PubMed          Journal:  Case Rep Oncol        ISSN: 1662-6575


  2 in total

1.  Yttrium-90 Selective Internal Radiation Therapy Plus Cryoablation for Recurrent Adrenocortical Carcinoma With Liver Metastases.

Authors:  Tung-Yen Lin; Kuan-Yu Lin; Hung-Yang Kuo; Kuo-How Huang; Chih-Yuan Wang; Yu-Lin Lin; Shyang-Rong Shih; Po-Chin Liang
Journal:  J Endocr Soc       Date:  2022-06-13

2.  Yttrium-90 radioembolization of isolated hepatic adrenocortical carcinoma metastases with negative surgical pathology.

Authors:  Sen Lu; Jasreman Dhillon; Julie Hallanger Johnson; Ghassan El-Haddad
Journal:  EJNMMI Res       Date:  2021-02-18       Impact factor: 3.138

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.